The use of botulinum toxin in the management of bruxism and facial arthromyalgia syndrome

Raluca A Dragomir,Otilia Boisteanu,Cristian Ilie Drochioi,Bogdan Dragomir,Alexandra Carp,Victor-Vlad Costan

doi:10.37897/rjmp.2020.1.15

Abstract

The use of botulinum toxin in the management of bruxism and facial arthromyalgia syndrome

Highlights

The spectrum of indication for botulinum toxin administration gradually increased over time as new benefits of this treatment were discovered, with wide applications ranging from cosmetic purposes, to treating muscular contractures, spasticity, dystonia and even neuromuscular pain [1,2,3,4]
The purpose of this study is to evaluate the effects of botulinum toxin administration in patients with bruxism and facial arthromyalgia syndrome, with previous conventional treatment attempts, regarding the improvement of clinical signs and symptoms
Clinical examination revealed the presence of temporomandibular joint pain upon palpation in nine cases, joint sounds in seven patients, limited jaw opening in six cases, painful muscle insertions in patients, muscle hypertrophy in nine cases, tooth surface loss in patients and important occlusal disturbances in five cases

Summary

Introduction

The effects of botulinum toxin administration were attributed mainly to the well-established property of inhibiting the release of acetylcholine at the synapse level, inducing absence of stimulation of the effector, whether it is a muscle or a gland with resulting obvious benefits in the treatment of conditions involving such structures [1]. Multiple studies underlined the effects of botulinum toxin concerning the inhibition of the release of several mediators of inflammation and peripheral neurotransmitters from the sensory nerve fibers, resulting in decreased pain [5,6,7]. The purpose of this study is to evaluate the effects of botulinum toxin administration in patients with bruxism and facial arthromyalgia syndrome, with previous conventional treatment attempts, regarding the improvement of clinical signs and symptoms The input of the neurotoxin administration in the multifactorial context of the disease has been the focus of many studies, but further research is still required to establish the outcomes of its clinical use in different scenarios [10,11].

Objectives

Methods

Results

Conclusion